Clinuvel Pharmaceuticals Ltd
ASX:CUV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
AU |
|
C
|
Credit Suisse Group AG
XHAM:CSX
|
CH |
|
Anheuser-Busch Inbev SA
MIL:ABI
|
BE |
|
S
|
Silgan Holdings Inc
F:SL3
|
US |
|
Inghams Group Ltd
ASX:ING
|
AU |
|
Bonduelle SA
PAR:BON
|
FR |
|
Powersoft SpA
MIL:PWS
|
IT |
|
Fortescue Metals Group Ltd
ASX:FMG
|
AU |
|
Power Finance Corporation Ltd
NSE:PFC
|
IN |
|
L
|
Longino & Cardenal SpA
MIL:LON
|
IT |
|
P
|
Palfinger AG
VSE:PAL
|
AT |
|
Cohort PLC
LSE:CHRT
|
UK |
|
El En SpA
MIL:ELN
|
IT |
Wall St Price Targets
CUV Price Targets Summary
Clinuvel Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for CUV is 24.54 AUD with a low forecast of 13.13 AUD and a high forecast of 41.16 AUD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is CUV's stock price target?
Price Target
24.54
AUD
According to Wall Street analysts, the average 1-year price target for CUV is 24.54 AUD with a low forecast of 13.13 AUD and a high forecast of 41.16 AUD.
What is the Revenue forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Revenue has been 39%. The projected CAGR for the next 8 years is 7%.
What is the Operating Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
9%
The compound annual growth rate for Operating Income over the next 8 years is 9%.
What is the Net Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
10%
The compound annual growth rate for Net Income over the next 8 years is 10%.
